SLN Silence Therapeutics Corp: שווי הפעילות העסקית

Silence Therapeutics management is currently optimizing internal regulations for large-scale trials, leveraging the authority of its scientists. The technology stack is based on AI modeling and partial automation of drug synthesis. This price action snapshot on GURU.Markets shows an Enterprise Value of 1153.04, confirming the company's drive for global leadership in the RNA interference segment through strategic alliances with corporate behemoths.

The development of RNA drugs and long-term royalties from pharma behemoths directly determine the dynamics of the total fundamental value of Silence Therapeutics (SLN). This indicator aggregates market capitalization and liabilities while subtracting cash, allowing an investor to assess the actual amount of capital required for a full buyout of the business, accounting for its net debt and the quality of existing assets.